DSST Substance Abuse common mistakes
DSST Substance Abuse · Understand the traps and how to avoid them.
Treating every psychoactive substance as producing the same withdrawal picture, so the candidate predicts severe autonomic withdrawal for cannabis or hallucinogens or misses the potentially fatal course of alcohol and benzodiazepine withdrawal.
Study time is concentrated on intoxication effects and drug categories, and the shared word 'withdrawal' invites a single template; candidates also assume that a substance being illegal or dangerous implies dangerous withdrawal.
What to do instead
Build a withdrawal table with columns for onset, peak, duration, autonomic signs, seizure or delirium risk, and first-line management. Mark alcohol, benzodiazepines, and barbiturates as the medically dangerous ones, and note that cannabis and hallucinogen discontinuation does not produce life-threatening autonomic withdrawal.
Confusing physical dependence with addiction, and therefore labelling a patient who develops tolerance and withdrawal on prescribed opioids or benzodiazepines as having a substance use disorder.
Tolerance and withdrawal are memorised as checklist items for dependence, and candidates transpose the older DSM dependence criteria onto the current use-disorder framework.
What to do instead
Separate the concepts explicitly: tolerance and withdrawal are expected pharmacological adaptations that can occur with supervised medical use, while a use disorder requires a problematic pattern such as loss of control, craving, continued use despite harm, and social or occupational impairment. Practise classifying short vignettes on that basis.
Mixing up the acute intoxication syndromes, for example attributing pinpoint pupils and respiratory depression to stimulants, or expecting dilated pupils and hypertension in opioid overdose.
Drug effects are memorised as lists of individual signs rather than as a coherent toxidrome, and stimulant and depressant profiles blur under exam pressure.
What to do instead
Memorise four toxidromes as clusters: opioid (pinpoint pupils, respiratory depression, sedation), sympathomimetic (mydriasis, tachycardia, hypertension, sweating, agitation), anticholinergic (dry skin, flushing, mydriasis, delirium, urinary retention), and sedative-hypnotic (sedation, ataxia, slurred speech, respiratory depression). Link each cluster to its antidote or supportive measure.
Overlooking over-the-counter and prescription products as causes of presenting symptoms, so a case of chronic cough, rebound congestion, or acetaminophen-related liver injury is attributed to an illicit drug.
Candidates equate 'substance abuse' with street drugs and forget that dextromethorphan, pseudoephedrine, antihistamines, laxatives, and caffeine are commonly misused, and that alcohol is present in many liquid preparations.
What to do instead
When a vignette gives a negative illicit-drug screen but persistent symptoms, run through an OTC differential: dextromethorphan for dissociative or serotonergic effects, stimulant decongestants for hypertension and insomnia, antihistamines for anticholinergic delirium, and acetaminophen for hepatic failure. Ask specifically about 'what do you take for your cough, congestion, or sleep'.
Assuming anabolic-androgenic steroid use is harmless or purely cosmetic, and missing the psychiatric, cardiovascular, and endocrine red flags in a muscular patient with irritability, acne, and testicular atrophy.
Steroids are often filed under 'performance drugs' rather than substances of misuse, and the presentation is gradual rather than an acute emergency, so it is not considered in the differential.
What to do instead
Attach a fixed cluster to steroid misuse: mood lability and aggression, acne and gynecomastia, testicular atrophy and infertility, hypertension and dyslipidaemia, and injection-site infection risk. Remember that withdrawal after cessation can bring depression and fatigue, and that sharing needles carries blood-borne virus risk.
Screening with a single yes-or-no question such as 'do you use drugs?' and treating a negative answer as exclusion of a substance problem.
Candidates want a fast rule-out and are uncomfortable with confrontation, and they underestimate denial, stigma, and fear of legal consequences in this population.
What to do instead
Use a validated multi-item tool and a non-judgemental frame: ask about each substance class separately, specify a time window such as the past year, ask about quantity and frequency, and follow up positives with brief intervention and referral. Note that a self-report negative does not override clinical signs such as track marks, nasal septal erosion, or unexplained liver enzyme elevation.
Misreading screening and confirmatory laboratory results, for example treating a positive immunoassay as definitive or failing to recognise that alcohol biomarkers such as GGT and MCV are indirect and non-specific.
The word 'screen' suggests a diagnostic test, and the different purposes of screening assays, chromatographic confirmation, and biomarkers are not distinguished during study.
What to do instead
Learn the two-step logic: immunoassay screening is fast and sensitive but prone to cross-reactivity, so positives are confirmed by a specific method such as gas chromatography-mass spectrometry. Know the windows of detection for common drugs and the limits of indirect alcohol markers, including that they reflect chronic heavy use rather than a single episode.
Ignoring co-occurring psychiatric illness by attributing all symptoms to substance use, or the reverse, without considering that the two commonly coexist.
The exam presents substance use as the headline problem, and candidates apply a single-cause explanation rather than a longitudinal or dual-diagnosis frame.
What to do instead
Ask whether symptoms persist during documented abstinence and whether they predate substance use. Remember that depression, anxiety, ADHD, and post-traumatic stress disorder frequently co-occur, that withdrawal itself can mimic depression or anxiety, and that integrated treatment of both conditions improves outcomes.
Assuming neurobiological reward is confined to dopamine in a single 'pleasure centre', and therefore misanswering items about tolerance, sensitisation, craving, and relapse.
Simplified teaching slogans stick better than circuit-level detail, and the roles of GABA, glutamate, endogenous opioids, and stress systems are under-studied.
What to do instead
Learn the mesolimbic dopamine pathway as the common reward route, then add the adaptations: downregulated dopamine signalling with chronic use, glutamate-driven cue reactivity and craving, and corticotropin-releasing factor involvement in stress-induced relapse. Link each mechanism to a clinical phenomenon such as tolerance, withdrawal dysphoria, or cue-triggered relapse.
Treating societal consequences as vague generalities, so items about impaired driving thresholds, workplace testing, fetal effects, or cost-shifting are answered by intuition rather than by specific facts.
This domain reads as common sense, so candidates skip targeted review and cannot distinguish legal limits, screening contexts, and population-level harms.
What to do instead
Anchor each societal topic to a concrete fact: the legal blood alcohol concentration limit for driving in the United States, the purpose and limits of workplace and pre-employment testing, the risks of alcohol and other substances in pregnancy including fetal alcohol spectrum disorders, and the public costs of emergency care, incarceration, and lost productivity. Review each with a one-line summary.
Missing the signs of injection-related infection or of a withdrawal emergency that needs immediate referral, and instead answering with a purely educational or outpatient-counselling option.
Candidates default to psychosocial interventions because those dominate substance-use treatment content, and they under-weight urgency cues such as fever, abscess, seizures, or delirium.
What to do instead
Scan each vignette for red flags first: fever with injection marks, spreading cellulitis, altered mental status, seizures, or autonomic instability. When present, choose the immediate medical option such as emergency evaluation and medically supervised withdrawal management, and reserve counselling or referral for stable patients without acute risk.